89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
–Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis (F4)– –Granted Priority Medicines (PRIME) status from the European Medicines Agency (EMA) for pegozafermin in the treatment of MASH with fibrosis and compensated cirrhosis– –Data from the 48-Week Extension Phase of the ENLIVEN Phase 2b Trial to be presented at the European Association for the Study of the Liver Congress (EASL)– SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024. "We are excited to have initiated ENLIGHTEN-Fibrosis, the first of two pivotal Phase 3 trials addressing MASH, and we are on track to begin the ENLIGHTEN-Cirrhosis trial for compensated cirrhotic MASH patients in the second qua
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.MarketBeat
- 89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- 89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Evercore ISI from $37.00 to $33.00. They now have an "outperform" rating on the stock.MarketBeat
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]Yahoo! Finance
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisGlobeNewswire
ETNB
Earnings
- 5/9/24 - Miss
ETNB
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/3/24 - Form 4
- ETNB's page on the SEC website